Emergent BioSolutions (EBS) Free Cash Flow Growth (5y) (2015 - 2026)
Emergent BioSolutions (EBS) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Emergent BioSolutions | 383.54 Mn | 222.04 Mn | 84.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.73% |
| Dec 31, 2025 | -21.16% |
| Sep 30, 2025 | -56.54% |
| Jun 30, 2025 | 2.21% |
| Mar 31, 2025 | -19.53% |
| Dec 31, 2024 | -20.19% |
| Sep 30, 2024 | 58.61% |
| Jun 30, 2024 | 20.60% |
| Mar 31, 2024 | -21.74% |
| Dec 31, 2023 | 39.70% |
| Sep 30, 2023 | -11.92% |
| Jun 30, 2023 | -53.02% |
| Mar 31, 2023 | -72.38% |
| Dec 31, 2022 | 32.95% |
| Sep 30, 2022 | -45.84% |
| Jun 30, 2022 | -25.13% |
| Mar 31, 2022 | -39.34% |
| Dec 31, 2021 | 59.24% |
| Sep 30, 2021 | 36.86% |
| Jun 30, 2021 | -4.65% |